After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...

EyePoint's Duravyu meets primary endpoint in Phase 2 DME trial, showing potential to compete with Regeneron's Eylea and Roche ...

LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

TD Cowen reiterated its Buy rating and $20.00 price target for EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT). This aligns with the broader analyst consensus, as InvestingPro data shows analyst targets ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) rose 10% Wednesday after the company reported positive six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...